Platelet-serotonin Dynamics: Elucidating Their Role in Pulmonary Arterial Hypertension

Farida Mindubayeva 1, Mariya Ospanova 2 * , Lyudmila Akhmaltdinova 2, Bibigul Tukbekova 3
More Detail
1 Department of Physiology, NCJSC «Karaganda Medical University», Karaganda, Kazakhstan
2 Institute of Life Sciences, NCJSC «Karaganda Medical University», Karaganda, Kazakhstan
3 Department of Pediatrics and Neonatology, NCJSC «Karaganda Medical University», Karaganda, Kazakhstan
* Corresponding Author
J CLIN MED KAZ, Volume 21, Issue 3, pp. 37-42.
OPEN ACCESS 121 Views 82 Downloads
Download Full Text (PDF)
Author Contributions: Conceptualization, M.O. and F.M.; validation, F.M.; formal analysis, L.A., M.O., F.M. and B.T.; investigation, L.A., M.O., F.M. and B.T.;
resources, M.O.; data curation, M.O., L.A. and B.T.; writing – original draft preparation, M.O.; writing – review and editing, F.M., L.A. and B.T.; visualization, L.A. and M.O.; supervision, F.M.; project administration, F.M.; funding acquisition, F.M. All authors have read and agreed to the published version of the manuscript.


Background and Objectives:
Pulmonary arterial hypertension (PAH) is a significant complication in pediatric patients with congenital heart disease (CHD). The role of platelets and serotonin in the pathogenesis of PAH has been increasingly recognized. This study aims to investigate the correlation between platelet count, serotonin levels, and PAH in children with CHD, and to understand the impact of surgical intervention on these parameters.

Material and Methods:
This study included 26 children with CHD and PAH (Group I) and an 11-child control group without PAH. Pre- and post-operative platelet counts, mean platelet volume (MPV), platelet distribution width (PDW), plateletcrit (PCT), and serotonin levels in plasma and platelets were measured. Group I underwent surgical correction for CHD, and the control group received no such intervention. Data were analyzed to determine the relationships between these hematological and biochemical markers and PAH.

Group I showed higher pre-operative platelet counts and serotonin levels compared to the control group. Post-surgical data indicated a significant decrease in platelet serotonin levels, aligning more closely with the control group. The study also observed lower plasma serotonin levels in the control group, suggesting altered serotonin metabolism in PAH patients.

The study suggests a strong association between elevated platelet counts, increased serotonin levels, and the presence of PAH in children with CHD. Surgical correction of CHD appears to normalize these parameters, indicating a potential pathophysiological link. These findings emphasize the need for further research to understand the underlying mechanisms and to explore targeted therapeutic strategies for PAH in pediatric CHD patients.


Mindubayeva F, Ospanova M, Akhmaltdinova L, Tukbekova B. Platelet-serotonin Dynamics: Elucidating Their Role in Pulmonary Arterial Hypertension. J CLIN MED KAZ. 2024;21(3):37-42.


  • Weatherald J, Reis A, et al. Pulmonary arterial hypertension registries: past, present and into the future. Eur Respir Rev. 2019; 28(154):1-2. DOI: 10.1183/16000617.0128-2019
  • Zijlstra W. Survival differences in pediatric pulmonary arterial hypertension: Clues to a better understanding of outcome and optimal treatment strategies. Am Coll Cardiol. 2014; 3(20):2159-2169. DOI: 10.1016/j.jacc.2014.02.575
  • Pascall E, Tulloh RMR. Pulmonary hypertension in congenital heart disease. Future Cardiol. 2018; 14(4):343–353. doi: 10.2217/fca-2017-0065
  • Iacobazzi D, Suleiman MS, et al. Cellular and molecular basis of RV hypertrophy in congenital heart disease. Heart. 2016; 102(1):12–17. doi: 10.1136/heartjnl-2015-308348
  • Rosenzweig EB, Krishnan U. Congenital Heart Disease-Associated Pulmonary Hypertension. Clin Chest Med. 2021; 42:9–18. DOI: 10.1016/j.ccm.2020.11.005
  • Diller GP, Kempny A, et al. Survival prospects of treatment naive patients with Eisenmenger: a systematic review of the literature and report of own experience. Heart. 2016; 100(17):1366–1372. DOI: 10.1136/heartjnl-2014-305690
  • Stępnowska E, Lewicka E, et al. Prognostic factors in pulmonary arterial hypertension: Literature review. Adv Clin Exp Med. 2017; 26(3):549–553. DOI: 10.17219/acem/61855
  • Davizon-Castillo P, Allawzi A, Sorrells M, et al. Platelet activation in experimental murine neonatal pulmonary hypertension. Physiological Reports. 2020; 8(5):1-14. doi: 10.14814/phy2.14386
  • Dees C, Akhmetshina A, et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. ExpMed. 2011; 208:961–972. DOI: 10.1084/jem.20101629
  • Santos-Gomes J, Gandra I, Adão R, et al. An Overview of Circulating Pulmonary Arterial Hypertension Biomarkers. Frontiers in Cardiovascular Medicine. 2022; 9:1-26.
  • Shajib MS, Khan WI. The role of serotonin and its receptors in activation of immune responses and inflammation. Acta Physiol (Oxf). 2015; 213:561–574. DOI: 10.1111/apha.12430
  • Kelley L. Biomarkers for pediatric pulmonary arterial hypertension – a call to collaborate. Frontiers in Pediatrics. Pediatric Pulmonology. 2014; 2:1-12.
  • Gaheen R, El Amrousy D, et al. Plasma copeptin levels in children with pulmonary arterial hypertension associated with congenital heart disease. Eur J Pediatr. 2021; 180:2889–2895. DOI: 10.1007/s00431-021-04060-9
  • Lannan KL, Phipps RP, et al. Thrombosis, platelets, microparticles and PAH: more than a lot. Drug Discovery Today. 2014; 13(83):1-6. doi: 10.1016/j.drudis.2014.04.001
  • Mese T, Guven B, Yilmazer MM, et al. Platelet activation markers in children with congenital heart disease associated with pulmonary arterial hypertension. Congenital Heart Disease. 2018; 13(4):506–511. DOI: 10.1111/chd.12616
  • Ismail EAR, Youssef OI. Platelet-Derived Microparticles and Platelet Function Profile in Children With Congenital Heart Disease. Clinical and Applied Thrombosis/Hemostasis. 2013; 19(4):424–432. DOI: 10.1177/1076029612456733
  • West JD, Carrier EJ, et al. Serotonin 2B receptor antagonism prevents heritable pulmonary arterial hypertension. PLoS One. 2016; 10(11):1-18. DOI: 10.1371/journal.pone.0148657
  • Hutcheson JD, Setola V, et al. Serotonin receptors and heart valve disease. Pharmacol Ther. 2011; 132:146–157. DOI: 10.1016/j.pharmthera.2011.03.008
  • Gray EA. Assessment of the serotonin pathway as a therapeutic target for pulmonary hypertension. Synchrotron Rad. 2013; 20:756-764. DOI: 10.1107/S0909049513021213
  • Sadoughi A, Roberts KE, Preston IR, et al. Use of selective serotonin reuptake inhibitors and outcomes in pulmonary arterial hypertension. Chest. 2013; 144:531–541. DOI: 10.1378/chest.12-2081
  • Mindubayeva F, Niyazova Y, Nigmatullina R, et al. Membrane serotonin transporter as a biomarker of pulmonary arterial hypertension in children with congenital heart defect. Research Journal of Pharmacy and Technology. 2020; 5(13):2435-2438. DOI:10.5958/0974-360X.2020.00436.9